This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is also posted in pdf form and as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full-text searching of over 8,000 entries. Comments and suggestions should be directed to

David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request an email version: Vaccines and Global Health: The Week in Review is published as a single email summary, scheduled for release each Saturday evening at midnight (EST/U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]
A. Milestones :: Perspectives :: Featured Journal Content
B. Emergencies
C. WHO; CDC [U.S., Africa, China]
D. Announcements
E. Journal Watch
F. Media Watch
UNICEF mourns death of Dr. Peter Salama
Statement by Henrietta Fore, UNICEF Executive Director
NEW YORK, 24 January 2020 – “The entire UNICEF family is deeply saddened by the sudden death of Dr. Peter Salama from a heart attack in Geneva.

“Pete was a tireless advocate for children, a committed humanitarian and a highly respected professional.

“He was an inspiring and caring leader across a number of roles within UNICEF, as Chief of Health and Nutrition in Afghanistan, as Representative in Ethiopia and Zimbabwe, as Regional Director for the Middle East and North Africa in Jordan, as Global Chief of Health and HIV and as Global Ebola Coordinator in New York.

“Pete left UNICEF in 2016 to join the World Health Organization as Executive Director of its Health Emergencies Programme before becoming Executive Director of its Division of Universal Health Coverage - Life Course.

“All of us who had the privilege of working with Pete knew that he embodied the spirit of UNICEF like few others.

“Our most heartfelt condolences to his wife, his three children and all his friends and colleagues around the world. He will be sorely missed.”

WHO mourns passing of Dr Peter Salama
24 January 2020 – Statement
The World Health Organization announces with deep sadness the sudden death of Dr Peter Salama, Executive Director of WHO’s Division for Universal Health Coverage – Life Course.

The Organization extends its most profound sympathies and condolences to Dr Salama’s family, friends and colleagues. He was 51 and leaves behind his wife and three children.

“Pete embodied everything that is best about WHO and the United Nations – professionalism, commitment and compassion,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Our hearts are broken.”

Dr Salama, a medical epidemiologist from Australia, joined WHO in 2016 as Executive Director of WHO’s Health Emergencies programme, which he led until 2019.

Before joining WHO, Dr Salama was Regional Director for the Middle East and North Africa at UNICEF, an organization that he joined in 2002.

He had also worked with Médecins Sans Frontières and Concern Worldwide in several countries in Asia and sub-Saharan Africa.

Wuhan+ – Novel Coronavirus [2019-nCoV]

Situation report - 4 - WHO
Novel Coronavirus (2019-nCoV)
24 January 2020
[Excerpt]
PREPAREDNESS AND RESPONSE
WHO:
:: WHO has published an updated advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV;
:: WHO has been in regular and direct contact with Chinese as well as Japanese, Korean and Thai authorities since the reporting of these cases. The three countries have shared information with WHO under the International Health Regulations. WHO is also informing other countries about the situation and providing support as requested;
:: On 2 January, the incident management system was activated across the three levels of WHO (country office, regional office and headquarters);
:: Developed the surveillance case definitions for human infection with 2019-nCoV and is updating it as the new information becomes available;
:: Developed interim guidance for laboratory diagnosis, clinical management, infection prevention and control in health care settings, home care for mild patients, risk communication and community engagement;
:: Prepared disease commodity package for supplies necessary in identification and management of confirmed patients;
:: Provided recommendations to reduce risk of transmission from animals to humans;
:: Utilizing global expert networks and partnerships for laboratory, infection prevention and control, clinical management and mathematical modelling;
:: Activation of R&D blueprint to accelerate diagnostics, vaccines, and therapeutics;
:: WHO is working with our networks of researchers and other experts to coordinate global work on surveillance, epidemiology, modelling, diagnostics, clinical care and treatment, and other ways to identify, manage the disease and limit onward transmission. WHO has issued interim guidance for countries, updated to take into account the current situation.

National Health Commission of the People's Republic of China
http://en.nhc.gov.cn/

Data key to staying ahead of pneumonia
China will continue to publicly post daily information on the new viral pneumonia outbreak and prevention and control measures taken by the government, the National Health Commission said on Jan 22.

CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019
OSLO, NORWAY. Jan 23, 2020 – CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the initiation of three programmes to develop vaccines against the novel coronavirus, nCoV-2019.

The programmes will leverage rapid response platforms already supported by CEPI as well as a new partnership. The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible.

The nCoV-2019 vaccine development efforts will build on existing partnerships with Inovio (Nasdaq: INO) and The University of Queensland (located in Brisbane, Australia). In addition, CEPI today announces a new partnership with Moderna, Inc., (Nasdaq: MRNA) and the U.S. National Institute of Allergy and Infectious Diseases.

All of these are pioneering technologies designed to speed up the development of vaccines against emerging threats such as nCoV-2019.

“Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work on the MERS coronavirus and rapid response platforms to speed up vaccine development. There are no guarantees of success, but we hope this work could provide a significant and important step forward in developing a vaccine for this disease. Our aspiration with these technologies is to bring a new pathogen from gene sequence to clinical testing in 16 weeks – which is significantly shorter than where we are now,” said Richard Hatchett, CEO of CEPI.

The term “platform technology” broadly refers to systems that use the same basic components as a backbone but can be adapted for use against different pathogens as needed by inserting new genetic or protein sequences.

CEPI has moved with great urgency and in coordination with WHO, who is leading the development of a coordinated international response, to promote the development of new vaccines against the emerging threat of nCoV-2019. The novel coronavirus represents the first new epidemic disease of note to emerge since CEPI’s founding at Davos in 2017, with the express intent that it should be ready to respond to epidemics rapidly and effectively, wherever they emerge...

CDC: Transcript of 2019 Novel Coronavirus (2019-nCoV) Response
Friday, January 24, 2020
[Excerpt]
Dr. Nancy Messonnier:
...To date, we have 63 of what we are calling patients under investigation or PUIs from 22 states. So far, only two have been confirmed positive and 11 tested negative. We anticipate by next week we'll begin regular reporting of case information on our website. There are likely to be many more PUIs identified in the coming days.

We have faced similar public health challenges before. Those outbreaks were complex and required a comprehensive public health response. This is what we are preparing for. We have an aggressive response with the goal of identifying potential cases early. We want to make sure these patients get the best and most appropriate care. This is a rapidly changing situation both abroad and domestically, and we are still learning. Let’s remember this virus is identified within the past month and there is much we don’t know yet. We are expecting more cases in the U.S., and we are likely going to see some cases among close contacts of travelers and human to human transmission.

Our goal is always to protect the health of Americans. We at CDC have our best people working on this problem. We have support across the entirety of the Federal Government. We have one of the strongest public health systems in the world. Again, while there are many unknowns, CDC believes that the immediate risk to the American public continues to be low at this time, but that the situation continues to evolve rapidly.

CDC recommends travelers avoid all non-essential travel to Wuhan. We also recommend people traveling to other parts of China practice certain health precautions, like avoiding contact with people who are sick and practicing good hand hygiene. Returning travelers with symptoms, or close contact with people confirmed with coronavirus, may be asked to take precautionary measures and there may be some disruptions. I want to thank those people in advance for their cooperation. Everyone can do their part here.

Although Chinese officials have closed transport within and out of Wuhan, China, CDC will continue to conduct enhanced screening at five designated airports: New York JFK, San Francisco, LAX, Chicago O’Hare and Atlanta Hartsfield-Jackson. We are currently evaluating the extent and duration of this enhanced screening. Every day we learn more and every day we assess to see if our guidance or response can be improved. As the response evolves, CDC will continue our aggressive public health response strategy. Thank you...

::::::::

Statement on the meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
23 January 2020
Statement, Geneva, Switzerland

The meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) regarding the outbreak of novel coronavirus 2019 in the People’s Republic of China, with exportations currently reported in the Republic of Korea, Japan, Thailand and Singapore, took place on Wednesday, 22 January 2020, from 12:00 to 16:30 Geneva time (CEST) and on Thursday, 23 January 2020, from 12:00 to 15:10. The Committee’s role is to give advice to the Director-General, who makes the final decision on the
The determination of a Public Health Emergency of International Concern (PHEIC). The Committee also provides public health advice or suggests formal temporary recommendations as appropriate.

**Proceedings of the meeting**

Members and advisors of the Emergency Committee were convened by teleconference.

The Director-General welcomed the Committee and thanked them for their support. He turned the meeting over to the Chair, Professor Didier Houssin. Professor Houssin also welcomed the Committee and gave the floor to the Secretariat.

On 22 January, representatives of WHO’s legal department and the department of compliance, risk management, and ethics briefed the Committee members on their roles and responsibilities.

Committee members were reminded of their duty of confidentiality and their responsibility to disclose personal, financial, or professional connections that might be seen to constitute a conflict of interest. Each member who was present was surveyed and no conflicts of interest were judged to be relevant to the meeting.

The Chair then reviewed the agenda for the meeting and introduced the presenters.

On 23 January, representatives of the Ministry of Health of the People’s Republic of China, Japan, Thailand, and the Republic of Korea updated the committee on the situation in their countries. There have been increased numbers of reported cases in China, with 557 confirmed as of today.

**Conclusions and Advice**

On 22 January, the members of the Emergency Committee expressed divergent views on whether this event constitutes a PHEIC or not. At that time, the advice was that the event did not constitute a PHEIC, but the Committee members agreed on the urgency of the situation and suggested that the Committee should be reconvened in a matter of days to examine the situation further.

After the announcement of new containment measures in Wuhan on 22 January, the Director-General asked the Emergency Committee to reconvene on 23 January to study the information provided by Chinese authorities about the most recent epidemiological evolution and the risk-management measures taken.

Chinese authorities presented new epidemiological information that revealed an increase in the number of cases, of suspected cases, of affected provinces, and the proportion of deaths in currently reported cases of 4% (17 of 557). They reported fourth-generation cases in Wuhan and second-generation cases outside Wuhan, as well as some clusters outside Hubei province. They explained that strong containment measures (closure of public-transportation systems in Wuhan City, as well as other nearby cities). After this presentation, the EC was informed about the evolution in Japan, Republic of Korea, and Thailand, and that one new possible case had been identified in Singapore.

The Committee welcomed the efforts made by China to investigate and contain the current outbreak.

The following elements were considered as critical:

- Human-to-human transmission is occurring and a preliminary R0 estimate of 1.4-2.5 was presented. Amplification has occurred in one health care facility. Of confirmed cases, 25% are reported to be severe. The source is still unknown (most likely an animal reservoir) and the extent of human-to-human transmission is still not clear.
Several members considered that it is still too early to declare a PHEIC, given its restrictive and binary nature.

**Based on these divergent views, the EC formulates the following advice:**

**To WHO**

The Committee stands ready to be reconvened in approximately ten days’ time, or earlier should the Director-General deem it necessary.

The Committee urged to support ongoing efforts through a WHO international multidisciplinary mission, including national experts. The mission would review and support efforts to investigate the animal source of the outbreak, the extent of human-to-human transmission, the screening efforts in other provinces of China, the enhancement of surveillance for severe acute respiratory infections in these regions, and to reinforce containment and mitigation measures. A mission would provide information to the international community to aid in understanding of the situation and its potential public health impact.

WHO should continue to provide all necessary technical and operational support to respond to this outbreak, including with its extensive networks of partners and collaborating institutions, to implement a comprehensive risk communication strategy, and to allow for the advancement of research and scientific developments in relation to this novel coronavirus.

In the face of an evolving epidemiological situation and the restrictive binary nature of declaring a PHEIC or not, WHO should consider a more nuanced system, which would allow an intermediate level of alert. Such a system would better reflect the severity of an outbreak, its impact, and the required measures, and would facilitate improved international coordination, including research efforts for developing medical counter measures.

**To the People’s Republic of China**

:: Provide more information on cross-government risk management measures, including crisis management systems at national, provincial, and city levels, and other domestic measures.
:: Enhance rational public health measures for containment and mitigation of the current outbreak.
:: Enhance surveillance and active case finding across China, particularly during the Chinese New Year celebration.
:: Collaborate with WHO and partners to conduct investigations to understand the epidemiology and the evolution of this outbreak, including specific investigations to understand the source of the novel coronavirus, notably the animal reservoir, and animals involved in the zoonotic transmission, as well as the understanding of its full potential for human-to-human transmission, and where transmission is taking place, the clinical features associated with infection, and the required treatment to reduce morbidity and mortality.
:: Continue to share full data on all cases with WHO, including genome sequences, and details of any health care worker infections or clusters.
:: Conduct exit screening at international airports and ports in the affected provinces, with the aims early detection of symptomatic travelers for further evaluation and treatment, while minimizing interference with international traffic.
:: Encourage screening at domestic airports, railway stations, and long-distance bus stations as necessary.

**To other countries**

It is expected that further international exportation of cases may appear in any country. Thus, all countries should be prepared for containment, including active surveillance, early
detection, isolation and case management, contact tracing and prevention of onward spread of
2019-nCoV infection, and to share full data with WHO.

Countries are required to share information with WHO according to the IHR.

Technical advice is available here. Countries should place particular emphasis on reducing
human infection, prevention of secondary transmission and international spread and
contributing to the international response though multi-sectoral communication and
collaboration and active participation in increasing knowledge on the virus and the disease, as
well as advancing research. Countries should also follow travel advice from WHO.

**To the global community**

As this is a new coronavirus, and it has been previously shown that similar coronaviruses
required substantial efforts for regular information sharing and research, the global community
should continue to demonstrate solidarity and cooperation, in compliance with Article 44 of the
IHR (2005), in supporting each other on the identification of the source of this new virus, its full
potential for human-to-human transmission, preparedness for potential importation of cases,
and research for developing necessary treatment.

The Director-General thanked the Committee for its advice.

::: :::

::: :::

**WHO – 146th session of the Executive Board**

**Main Documents** [selected documents/Editor’s text bolding]]

**EB146/1 Rev.1**
Provisional agenda

**EB146/1(annotated)**
Provisional agenda (annotated)

**EB146/6**
Follow-up to the high-level meetings of the United Nations General Assembly on health-related
issues
Universal health coverage: moving together to build a healthier world

**EB146/7**
Follow-up to the high-level meetings of the United Nations General Assembly on health-related
issues
Political declaration of the third high-level meeting of the General Assembly on the prevention
and control of non-communicable diseases

**EB146/8**
Global vaccine action plan

**EB146/9**
Accelerating the elimination of cervical cancer as a global public health problem
Ending tuberculosis
Progress in implementing the global strategy and targets for tuberculosis prevention, care and control after 2015 (the End TB Strategy)

Ending tuberculosis
Draft global strategy for tuberculosis research and innovation

Neglected tropical diseases

Global strategy and plan of action on public health, innovation and intellectual property

Public health emergencies: preparedness and response
Independent Oversight and Advisory Committee for the WHO Health Emergencies Programme

Public health preparedness and response
WHO’s work in health emergencies

Influenza preparedness

The public health implications of implementation of the Nagoya Protocol

Public health emergencies: preparedness and response
Cholera prevention and control

Poliomyelitis
Polio eradication

Poliomyelitis
Polio transition planning and polio post-certification

Emergencies
Ebola – DRC+
Public Health Emergency of International Concern (PHEIC)

Ebola Outbreak in DRC 76: 21 January 2020
Situation Update
From 13 to 19 January 2020, 15 new confirmed cases of Ebola virus disease (EVD) were reported from North Kivu Province in the Democratic Republic of the Congo. The cases were reported from Beni (9 cases) and Mabalako (6 cases) Health Zones and all were linked to a confirmed case in a known chain of transmission...

:::

POLIO
Public Health Emergency of International Concern (PHEIC)
http://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 22 January 2020
:: The GPEI Polio Partners Group convened the eighth annual technical workshop on 6 December 2019 where a global overview of the status of poliovirus detection was presented among other polio updates. The meeting presentations are now available here.

Summary of new viruses this week (AFP cases and ES positives):
:: Afghanistan: one WPV1 case and three WPV1-positive environmental samples
:: Pakistan: two WPV1 cases, four WPV1-positive environmental samples and six cVDPV2 cases
:: Democratic Republic of the Congo (DR Congo): ten cVDPV2 cases
:: Côte d’Ivoire: two cVDPV2 positive environmental samples
:: Ghana: two cVDPV2 positive environmental samples
:: Malaysia: two cVDPV1 cases
:: Philippines: two cVDPV2 cases and two cVDPV2 positive environmental samples
:: Togo: one cVDPV2 case

:::

Rotary and the Bill & Melinda Gates Foundation extending fundraising partnership to eradicate polio
Partnership will infuse an additional US$450 million into global polio eradication effort
EVANSTON, Ill., Jan. 22, 2020 /PRNewswire/ -- Rotary and the Bill & Melinda Gates Foundation are renewing their longstanding partnership to end polio, announcing a joint commitment of up to $450 million to support the global polio eradication effort...

...In addition to the extended funding partnership with the Gates Foundation, Rotary is also announcing US$45 million in funding for polio eradication efforts in countries throughout Africa (Angola, Ethiopia, Mali, Nigeria, Somalia and South Sudan), and Asia (Afghanistan, Pakistan, Papua New Guinea, Pakistan and the Philippines). The funding will help support crucial polio eradication activities such as immunization and disease detection, research, and community mobilization...

:::
Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

**WHO Grade 3 Emergencies** [to 25 Jan 2020]

**Democratic Republic of the Congo**
:: Ebola Outbreak in DRC 76: 21 January 2020
[See Ebola above for detail]

Mozambique floods - No new digest announcements identified
Nigeria - No new digest announcements identified
Somalia - No new digest announcements identified
South Sudan - No new digest announcements identified
Syrian Arab Republic - No new digest announcements identified
Yemen - No new digest announcements identified

---

**WHO Grade 2 Emergencies** [to 25 Jan 2020]

**Angola**
:: Angola honours WHO Representative at end of mission 22 January 2020

**Measles in Europe**
:: Strengthening response to measles outbreak in Ukraine 22-01-2020

Afghanistan - No new digest announcements identified
Burkina Faso [in French] - No new digest announcements identified
Burundi - No new digest announcements identified
Cameroon - No new digest announcements identified
Central African Republic - No new digest announcements identified
Ethiopia - No new digest announcements identified
HIV in Pakistan - No new digest announcements identified
Iran floods 2019 - No new digest announcements identified
Iraq - No new digest announcements identified
Libya - No new digest announcements identified
Malawi floods - No new digest announcements identified
MERS-CoV - No new digest announcements identified
Myanmar - No new digest announcements identified
Niger - No new digest announcements identified
occupied Palestinian territory - No new digest announcements identified
Sudan - No new digest announcements identified
Ukraine - No new digest announcements identified
Zimbabwe - No new digest announcements identified

---
**WHO Grade 1 Emergencies** [to 25 Jan 2020]
Chad - No new digest announcements identified
Djibouti - No new digest announcements identified
Kenya - No new digest announcements identified
Mali - No new digest announcements identified
Namibia - viral hepatitis - No new digest announcements identified
Tanzania - No new digest announcements identified

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises.
Syrian Arab Republic - No new digest announcements identified
Yemen - No new digest announcements identified

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
CYCLONE IDAI and Kenneth - No new digest announcements identified
EBOLA OUTBREAK IN THE DRC - No new digest announcements identified

WHO & Regional Offices [to 25 Jan 2020]
**Message for World Leprosy Day 2020**
24 January 2020  Statement

**Effective outbreak response reduces the risk of measles spread in the Pacific**
Joint WHO-UNICEF statement on Pacific measles situation

In 2019, the Pacific saw the re-emergence of measles, with outbreaks declared in Samoa, Tonga, Fiji and American Samoa, and cases reported in Kiribati. For Samoa, the country experienced a widespread measles outbreak which had significant impact upon the country’s population and health system. The disease has cost lives, with infants and young children being most affected.

In response to the identification of measles in the region, many Pacific countries and areas have made serious efforts to close immunity gaps in their population and strengthen infectious disease prevention, surveillance and response systems. These efforts align to the core public health capacities required by all countries under the International Health Regulations (IHR) 2005, and critical to preventing and controlling the spread of infectious diseases, such as measles.

The governments of Samoa, Tonga and Fiji, have conducted vaccination campaigns aimed at closing immunity gaps in their populations to stop the transmission of the virus. These
immunization activities are bringing the outbreaks under control. In Samoa, the mass immunization campaign which targeted individuals aged six months to 60 years achieved 95 per cent vaccination coverage, the rate needed to prevent measles transmission in a population. Fiji and Tonga continue immunizing those most at risk of measles to meet the target of 95 per cent and ensure that populations are protected. Other Pacific countries and areas have also conducted supplementary immunization activities to reduce the risk of potential measles outbreaks.

Due to the public health efforts of Pacific countries and areas, the risk of measles spreading in Samoa and in other Pacific Island countries and areas has notably reduced...

Weekly Epidemiological Record, 24 January 2020, vol. 95, 04 (pp. 25–36)
Global Advisory Committee on Vaccine Safety, 4–5 December 2019

Calls for consultants / proposals
Health impact and cost-effectiveness of introduction of diphtheria, tetanus and pertussis booster doses in low- and middle-income countries pdf, 1.05Mb
Deadline for applications: 14 February 2020

WHO African Regions Immunization Technical Advisory Group (RITAG)
:: Call for nominations pdf, 147kb  Deadline for applications: 28 February 2020
:: RITAG Terms of Reference pdf, 211kb
:: RITAG application annexes pdf, 91kb

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
No new digest content identified.

WHO Region of the Americas PAHO
:: PAHO Director urges readiness to detect cases of new coronavirus in the Americas (01/24/2020)
:: Haiti reaches one-year free of Cholera (01/23/2020)
:: PAHO issues epidemiological alert on Novel Coronavirus for the Americas (01/20/2020)

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: 2019-nCoV outbreak: first cases confirmed in Europe 25-01-2020
:: Novel coronavirus outbreak in China – What does it mean for Europe? 24-01-2020
:: New report reveals the role of physical activity in preventing and treating cardiovascular diseases 22-01-2020
WHO Eastern Mediterranean Region EMRO
No new digest content identified.

WHO Western Pacific Region
No new digest content identified.

CDC/ACIP [to 25 Jan 2020]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases
Transcript of 2019 Novel Coronavirus (2019-nCoV) Response
Friday, January 24, 2020
[See Milestones above for detail]

Marburg Virus Found Circulating in Bats in West Africa
Friday, January 24, 2020

Second Travel-related Case of 2019 Novel Coronavirus Detected in United States
Friday, January 24, 2020

Transcript of Update on 2019 Novel Coronavirus (2019-nCoV)
Tuesday, January 21, 2020

First Travel-related Case of 2019 Novel Coronavirus Detected in United States
Tuesday, January 21, 2020

Africa CDC  [to 25 Jan 2020]
http://www.africacdc.org/
News
No new digest content identified.

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

National Health Commission of the People's Republic of China
http://en.nhc.gov.cn/
[See Milestones above for coronavirus updates]
Announcements

**Paul G. Allen Frontiers Group** [to 25 Jan 2020]
News
No new digest content identified.

**BMGF - Gates Foundation** [to 25 Jan 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
JANUARY 21, 2020
**Bill & Melinda Gates Foundation Statement on Creation of Nonprofit Agricultural Research Institute**

SEATTLE, January 21, 2020 – The Bill & Melinda Gates Foundation is in the process of creating a new 501(c)(3) nonprofit, Bill & Melinda Gates Agricultural Innovations, LLC, which seeks to accelerate the development of innovations supported by the foundation’s Agricultural Development team. The entity, to be known as Gates Ag One, aims to speed up efforts to provide smallholder farmers in developing countries, many of whom are women, with access to the affordable tools and innovations they need to sustainably improve crop productivity and adapt to the effects of climate change.

**Bill & Melinda Gates Medical Research Institute** [to 25 Jan 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

**CARB-X** [to 25 Jan 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 25 Jan 2020]
http://cepi.net/
Latest news
**CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019**
23 Jan 2020
[See Milestones above for detail]

**Clinton Health Access Initiative, Inc. (CHAI)** [to 25 Jan 2020]
https://clintonhealthaccess.org/
News & Press Releases
No new digest content identified.

**EDCTP** [to 25 Jan 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

**Emory Vaccine Center** [to 25 Jan 2020]
http://www.vaccines.emory.edu/
No new digest content identified.

**European Medicines Agency** [to 25 Jan 2020]
News & Press Releases
News: Martina Schüssler-Lenz re-elected as chair of Committee for Advanced Therapies
Last updated: 24/01/2020

Press release: Ten recommendations to unlock the potential of big data for public health in the EU
Last updated: 20/01/2020
Ten recommendations to unlock the potential of big data for public health in the EU
(PDF/175.06 KB) (new) First published: 20/01/2020 EMA/689902/2019

**European Vaccine Initiative** [to 25 Jan 2020]
http://www.euvaccine.eu/news-events
No new digest content identified.

**FDA** [to 25 Jan 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
No new digest content identified.
Fondation Merieux  [to 25 Jan 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi  [to 25 Jan 2020]
https://www.gavi.org/
24 January 2020
Gavi statement following the death of Peter Salama

23 January 2020
World leaders commit to Gavi’s vision to protect the next generation with vaccines
As Gavi celebrates its 20th anniversary at Davos, Germany and the Bill & Melinda Gates Foundation pledged catalytic support to Gavi, citing remarkable progress since 2000

Davos, 23 January 2020 – Global leaders committed to Gavi, the Vaccine Alliance’s vision to immunise hundreds of millions of children in the world’s poorest countries as they celebrated Gavi’s 20th anniversary at the World Economic Forum (WEF), citing remarkable progress since its inception in 2000.

Demonstrating outstanding leadership in global health, Chancellor Angela Merkel announced at WEF that Germany will commit €600 million for the 2021-25 five-year period...

... The Bill & Melinda Gates Foundation also announced on the sidelines of the World Economic Forum in Davos that it will renew its US$ 75 million contribution to the Gavi Matching Fund, an innovative public-private funding mechanism that secures resources to incentivise private sector investments in immunisation...

GHIT Fund  [to 25 Jan 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

Global Fund  [to 25 Jan 2020]
News & Stories
News
Global Fund Appoints New Head of Technical Advice & Partnerships
24 January 2020
GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria today announced the appointment of Michael Byrne as Head of the Technical Advice & Partnerships Department as the Global Fund strengthens technical expertise in disease teams.
““To step up the fight and most effectively leverage additional funds, we are elevating the capacity of our disease teams to help achieve global targets,” said Peter Sands, Executive Director of the Global Fund. "Michael will lead these efforts, and they should make a significant difference in our work with partners to accelerate progress against HIV, TB and malaria.”
Byrne brings 30 years of experience in international development including 13 years at the Global Fund.

**News**

**Global Fund Grant in the Democratic People’s Republic of Korea**
23 January 2020
The Global Fund has reached agreement with partners for a consolidated grant for tuberculosis and malaria in the Democratic People’s Republic of Korea, and implementation of the grant has begun.

Under this grant, the drug-susceptible tuberculosis and malaria component will be implemented by UNICEF and the World Health Organization. The multidrug-resistant tuberculosis (MDR-TB) component will be implemented by the Eugene Bell Foundation. With these revised implementation arrangements, the Global Fund is confident that partners can serve more people affected by tuberculosis and malaria, and achieve required levels of assurance that the grant is being implemented effectively.

The agreement was made possible by extensive collaboration by technical and development partners, and by the Government of DPRK. The Global Fund remains committed to supporting the health of people in DPRK, and thanks all partners for their continuous cooperation and collaboration during the grant negotiations.

**Voices**

**Ending Tuberculosis is Good for Business - New Initiative Launched to End Tuberculosis in the Workplace**
22 January 2020

**Hilleman Laboratories** [to 25 Jan 2020]
http://www.hillemanlabs.org/
*News*
No new digest content identified.

**Human Vaccines Project** [to 25 Jan 2020]
http://www.humanvaccinesproject.org/media/press-releases/
*Press Releases*
No new digest content identified.

**IAVI** [to 25 Jan 2020]
https://www.iavi.org/newsroom
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*
No new digest content identified.
International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

IFFIm
http://www.iffim.org/
No new digest content identified.

IFRC  [to 25 Jan 2020]
Selected Press Releases, Announcements
No new digest content identified.

IVAC  [to 25 Jan 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
No new digest content identified.

IVI  [to 25 Jan 2020]
http://www.ivi.int/
Selected IVI News & Announcements
No new digest content identified.

JEE Alliance  [to 25 Jan 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

MSF/Médecins Sans Frontières  [to 25 Jan 2020]
http://www.msf.org/
Latest [Selected Announcements]
Greece
Greece denies healthcare to seriously ill refugee children on Lesbos
Press Release 23 Jan 2020

Access to medicines
Our 2020 wishlist - five New Year's resolutions for medical care
Campaign 22 Jan 2020

Access to medicines
Gavi must ensure more children get new, more affordable pneumonia vaccine
Press Release 21 Jan 2020
:: A new vaccine against one of the world’s deadliest childhood diseases – pneumonia – is now available at a more affordable price than existing vaccines.
:: Vaccine funding organisation, Gavi, the Vaccine Alliance, has a $1.5 billion funding programme for the pneumonia vaccine, of which 80 per cent has already been paid to two pharma giants.
:: MSF urges Gavi – and WHO, UNICEF and the Gates Foundation – to ensure that the remaining amount is spent to ensure access to this third, more affordable, vaccine to protect children.

National Vaccine Program Office - U.S. HHS [to 25 Jan 2020]
https://www.hhs.gov/vaccines/about/index.html

NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

Update
The Fight Against Cervical Cancer Starts with HPV Vaccination

NIH [to 25 Jan 2020]

Selected News Releases
NIH officials discuss novel coronavirus that recently emerged in China
January 23, 2020 — Research underway to address latest viral threat:

PATH [to 25 Jan 2020]
https://www.path.org/media-center/

Selected Announcements
No new digest content identified.

Sabin Vaccine Institute [to 25 Jan 2020]
http://www.sabin.org/updates/pressreleases

Statements and Press Releases
No new digest content identified.

UNAIDS [to 25 Jan 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
23 January 2020
Empowering young people living with HIV to become agents of change in Thailand

20 January 2020

Supporting communities to be involved in the AIDS response in Thailand

20 January 2020

**Cash transfer schemes reduce the chances of adolescent girls and young women contracting HIV**

Efforts aimed at redressing gender inequalities and socioeconomic inequities can mitigate factors that fuel the HIV epidemic.

In a study in Eswatini, cash transfers aimed at keeping adolescent girls and young women in school and giving them greater financial independence resulted in the odds of the recipients becoming HIV-positive being 25% lower than for people who were not eligible for the incentive.

Studies from Eswatini, Lesotho, Malawi and the United Republic of Tanzania show that cash transfers help young people, especially girls, stay in school longer and do better in their studies. Other evidence indicates that cash grants that enable girls to continue their schooling also delay their sexual debut, increase their use of health services, reduce teen pregnancies and early marriage, and can promote safer sexual behaviours.

**UNICEF** [to 25 Jan 2020]
https://www.unicef.org/media/press-releases

*Selected Statements, Press Releases, Reports*

**Press release**

**UNICEF mourns death of Dr. Peter Salama**
Statement by Henrietta Fore, UNICEF Executive Director
24/01/2020

**Press release**

**On World Education Day, UNICEF unveils latest innovation to improve education in emergencies: The High Performance Tent**
23/01/2020

**Press release**

**1 in 3 adolescent girls from the poorest households has never been to school**
As the World Economic Forum Annual Meeting begins tomorrow and education ministers convene at the Education World Forum today, UNICEF urges policy-makers to address 'shameful' disparities in public education spending
19/01/2020

**Vaccination Acceptance Research Network (VARN)** [to 25 Jan 2020]
https://vaccineacceptance.org/news.html#header1-2r

No new digest content identified.

**Vaccine Confidence Project** [to 25 Jan 2020]
http://www.vaccineconfidence.org/
The European Regional Office of the Vaccine Confidence Project™

Professor Heidi Larson has recently joined the Centre for the Evaluation of Vaccination (CEV), University of Antwerp, as associate professor, as the CEV at the Antwerp University will host the European Regional Office of the Vaccine Confidence Project™ as of May 15, 2019, and will closely collaborate with Vaccine Confidence Project partners at European level on implementing the Vaccine Confidence Index™ and developing and evaluating interventions to address vaccine hesitancy.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 25 Jan 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
Newsletter - January 2020
Announcements: December webinar archived

Wellcome Trust  [to 25 Jan 2020]
https://wellcome.ac.uk/news
No new digest content identified.

The Wistar Institute  [to 25 Jan 2020]
Press Release
Jan. 24, 2020
TP53 Genetic Variant Found in Individuals of African Descent is Linked to Iron Overload but May Improve Response to Malaria
Iron accumulation and defects in the antibacterial function of macrophages caused by the P47S variant result in a less severe inflammatory response.

Press Release
Jan. 23, 2020
Wistar Joins Global Effort to Expedite Coronavirus Vaccine Development for Outbreak Originating in China
Coalition for Epidemic Preparedness Innovations Supports DNA Vaccine Based on Key Wistar Technology.
[See detail under Coronavirus above]

World Organisation for Animal Health (OIE)  [to 25 Jan 2020]
No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine]  [to 25 Jan 2020]
No new digest content identified.
**BIO** [to 25 Jan 2020]
Press Releases
No new digest content identified.

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 25 Jan 2020]
http://www.dcvmn.org/
News
No new digest content identified.

**IFPMA** [to 25 Jan 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

**PhRMA** [to 25 Jan 2020]
http://www.phrma.org/
Selected Press Releases, Statements
No new digest content identified.

**Industry Watch** [to 25 Jan 2020]
:: Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults
*University of Louisville Named First Center of Excellence*
January 23, 2020

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the launch of its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults. Pfizer Vaccines has designated the University of Louisville as its first Center of Excellence with a second global center anticipated in the first half of 2020.

“The Centers of Excellence will complete comprehensive, disease surveillance and real-world vaccine effectiveness studies, which are distinctly different from clinical safety and efficacy research,” said Luis Jodar, Pfizer Vaccines, Chief Medical and Scientific Affairs Officer. “With strategically located research centers around the world, we anticipate being able to better define and understand global disease burden in adults and vaccine effectiveness, which will help provide robust evidence to national policymakers and health officials who develop recommendations for the use of vaccines in immunization programs worldwide.”

As Pfizer’s first Center of Excellence site, the University of Louisville will initially conduct two separate, large population-based epidemiological studies in adults: a one-year study of the incidence of infectious diarrhea with funding provided by Pfizer up to $6.5 million and a one-year study of the incidence of pneumonia with funding provided by Pfizer up to $4.5 million...
:: Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna’s mRNA vaccine technology

January 23, 2020

:: Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus Jan 23, 2020

* * * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control
February 2020 Volume 48, Issue 2, p123-238
http://www.ajicjournal.org/current
[New issue; No digest content identified]

American Journal of Preventive Medicine
February 2020 Volume 58, Issue 2, p165-312
http://www.ajpmonline.org/current
Research Articles
Hepatitis B Birth Dose Effects on Childhood Immunization in the U.S.
Daniel T. Vader, Brian K. Lee, Alison A. Evans
p208–215
Published in issue: February 2020

American Journal of Public Health
February 2020  11(2)
http://ajph.aphapublications.org/toc/ajph/current
[New issue; No digest content identified]

American Journal of Tropical Medicine and Hygiene
Volume 101, Issue 6, 2019
Debate

Legal and ethical framework for global health information and biospecimen exchange - an international perspective

The progress of electronic health technologies and biobanks holds enormous promise for efficient research. Evidence shows that studies based on sharing and secondary use of data/samples have the potential to significantly advance medical knowledge. However, sharing of such resources for international collaboration is hampered by the lack of clarity about ethical and legal requirements for transfer of data and samples across international borders.
The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence

Participation in randomized controlled trials (RCTs) may be quite demanding and could represent an important burden for patients. We aimed to explore this research burden (i.e., the psychological, physical, an...

Authors: Nivantha Naidoo, Van Thu Nguyen, Philippe Ravaud, Bridget Young, Philippe Amiel, Daniel Schanté, Mike Clarke and Isabelle Boutron
Citation: BMC Medicine 2020 18:6
Published on: 20 January 2020

Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services

Routine immunization programs face many challenges in settings such as Papua New Guinea with dispersed rural populations, rugged geography and limited resources for transport and health. Low routine coverage c...

Authors: Christopher J. Morgan, Olga P. M. Saweri, Nicholas Larme, Elizabeth Peach, Pele Meleopia, Lucy Au, Michelle J. L. Scoullar, Mohammad Salim Reza, Lisa M. Vallely, Barbara I. McPake and James G. Beeson
Citation: BMC Public Health 2020 20:100
Content type: Research article
Published on: 23 January 2020
BMJ Open
January 2020 - Volume 10 - 1
http://bmjopen.bmj.com/content/current
[Reviewed earlier]

Bulletin of the World Health Organization
Volume 98, Number 1, January 2020, 1-76
https://www.who.int/bulletin/volumes/98/1/en/
[Reviewed earlier]

Child Care, Health and Development
Volume 46, Issue 1  Pages: 1-153  January 2020
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Therapeutics
December 2019 Volume 41, Issue 12, p2461-2680
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 16 Issue 6, December 2019
https://journals.sagepub.com/toc/ctja/16/6
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 25 Jan 2020]
[No new digest content identified]

Contemporary Clinical Trials
Volume 89  February 2020
[New issue; No digest content identified]

The CRISPR Journal
Volume 2, Issue 6 / December 2019
https://www.liebertpub.com/toc/crispr/2/6
[Reviewed earlier]
Current Genetic Medicine Reports  
Volume 7, Issue 4, December 2019  
https://link.springer.com/journal/40142/7/4  
[Reviewed earlier]

Current Opinion in Infectious Diseases  
February 2020 - Volume 33 - Issue 1  
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx  
[Reviewed earlier]

Developing World Bioethics  
Volume 19, Issue 4 Pages: 187-247 December 2019  
https://onlinelibrary.wiley.com/toc/14718847/current  
[Reviewed earlier]

Development in Practice  
Volume 29, Issue 8, 2019  
http://www.tandfonline.com/toc/cdip20/current  
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness  
Volume 13 - Issue 5-6 - December 2019  
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/  
[Reviewed earlier]

Disasters  
Volume 44, Issue 1 Pages: 1-232 January 2020  
https://onlinelibrary.wiley.com/toc/14677717/current  
[Reviewed earlier]

EMBO Reports  
Volume 21 Issue 1 7 January 2020  
https://www.embopress.org/toc/14693178/current  
[Reviewed earlier]

Emerging Infectious Diseases  
Volume 26, Number 2—February 2020  
http://wwwnc.cdc.gov/eid/  
Perspective
**Middle East Respiratory Syndrome Coronavirus Transmission** [PDF - 442 KB - 8 pages]
M. E. Killerby et al.

*Synopses*

**Public Health Program for Decreasing Risk for Ebola Virus Disease Resurgence from Survivors of the 2013–2016 Outbreak, Guinea** [PDF - 493 KB - 6 pages]
M. Keita et al.

**Epidemics**
Volume 29  December 2019
[Reviewed earlier]

**Epidemiology and Infection**
Volume 148 - 2020
[https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue](https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue)
[New issue; No digest content identified]

**Ethics & Human Research**
Volume 42, Issue 1  Pages: 1-40  January–February 2020

*Off-Trial Access :: Deception :: Crowdsourced Research :: Single IRBs*

**Articles**

**Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs**
Carolyn Riley Chapman, Jared Eckman, Alison S. Bateman-House
Pages: 2-13
First Published: 22 January 2020

**Crowdsourced Research: Vulnerability, Autonomy, and Exploitation**
Adrian Kwek
Pages: 22-35
First Published: 22 January 2020

**The European Journal of Public Health**
Volume 30, Issue 1, February 2020
[https://academic.oup.com/eurpub/issue/30/1](https://academic.oup.com/eurpub/issue/30/1)

*Health policy*

**Cost-effectiveness of public health interventions against human influenza pandemics in France: a methodological contribution from the FLURESP European Commission project**
Ariel Beresniak, Caterina Rizzo, John Oxford, Paweł Goryński, Adriana Pistol ...
Individual preferences for voluntary vs. mandatory vaccination policies: an experimental analysis
Nicolas W Meier, Robert Böhm, Lars Korn, Cornelia Betsch
Eur J Public Health, Volume 30, Issue 1, February 2020, Pages 50–55,
https://doi.org/10.1093/eurpub/ckz181

Infectious disease
Identifying people at risk for influenza with low vaccine uptake based on deprivation status: a systematic review
Vladimir Vukovic, Roberto Lillini, Silvia Lupi, Francesca Fortunato, Michela Cicconi ...
Eur J Public Health, Volume 30, Issue 1, February 2020, Pages 132–141,
https://doi.org/10.1093/eurpub/cky264

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 25 Jan 2020]
[No new digest content identified]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 25 Jan 2020]
[No new digest content identified]

Global Health Action
Volume 12, 2019 Issue 1
https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList
[No new digest content identified]

Global Health: Science and Practice (GHSP)
Vol. 7, No. 4 December 23, 2019
http://www.ghspjournal.org/content/current
[Reviewed earlier]

Global Public Health
Volume 15, 2020 Issue 1
http://www.tandfonline.com/toc/rgph20/current
[Reviewed earlier]

Globalization and Health
http://www.globalizationandhealth.com/
[No new digest content identified]
Health Affairs
Vol. 39, No. 1 January 2020
https://www.healthaffairs.org/toc/hlthaff/current

*Patient Costs, Bundled Payment & More*
[New issue; No digest content identified]

Health and Human Rights
Volume 21, Issue 2, December 2019

*Special Section: Abortion in the Middle East and North Africa*
*Special Section: Abortion Law Reform*
*Special Section: Human Rights for Health across the United Nations*
[Reviewed earlier]

Health Economics, Policy and Law
Volume 15 - Issue 1 - January 2020
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 34, Issue Supplement_3, December 2019
https://academic.oup.com/heapol/issue/34/Supplement_3

*Access to Medicines through Health Systems in Low- and Middle-Income Countries*
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 25 Jan 2020]

*A scoping review of the uses and institutionalisation of knowledge for health policy in low- and middle-income countries*

There is growing interest in how different forms of knowledge can strengthen policy-making in low- and middle-income country (LMIC) health systems. Additionally, health policy and systems researchers are incre...

Authors: Adam D. Koon, Lauren Windmeyer, Maryam Bigdeli, Jodi Charles, Fadi El Jardali, Jesse Uneke and Sara Bennett
Citation: Health Research Policy and Systems 2020 18:7
Content type: Review
Published on: 20 January 2020

Human Gene Therapy
Volume 31, Issue 1-2 / January 2020
2020: Gene Therapy Enters Its Fourth Decade
Terence R. Flotte and Guangping Gao
Published Online: 21 Jan 2020

Reviews Free
Public Acceptability of Gene Therapy and Gene Editing for Human Use: A Systematic Review
Juliette Delhove, Ivana Osenk, Ivanka Prichard, and Martin Donnelley
Pages: 20–46
Published Online: 5 December 2019
https://doi.org/10.1089/hum.2019.197

Abstract
Gene therapy and gene editing technologies are complex and it can be difficult for the public to understand their possible benefits or side effects. However, patient and public support is critical for the successful adoption of any new technology. Given the recent advances in gene therapy and gene editing, their potential clinical benefits, and the significant attention that has been given to the first-known successful attempt at permanent and heritable changes to the human genome, a systematic review was performed to assess beliefs and attitudes toward gene therapy and gene editing for human use, and to highlight the factors that influence acceptability. A systematic search following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was undertaken in April 2018 to identify articles examining opinions and attitudes regarding the acceptability of gene therapy and gene editing. Overall, 1,561 records were retrieved from 4 databases (Ovid Medline, PsycINFO, Scopus, and Web of Science). Duplicates were removed, and titles and abstracts independently screened, leaving 86 full-text articles assessed for eligibility. Following full-text review, 33 were included, with 5 articles added after forward/backward searching. An additional three articles were added following an updated search in March 2019 (total n=41). Findings from the studies were integrated according to common themes: the impact of demographics; risks versus benefits of success; treatment specifics (e.g., medical vs. other reasons; disease severity and status; somatic vs. germ line; and mode of delivery); moral or ethical issues; and changes with time. In general, perceptions were positive, particularly for medical reasons and fatal diseases, but were also influenced by perceived risk. Somatic therapies had higher levels of acceptability than germ line therapies. While available in various forms, limitations exist in the measurement of perceptions of gene therapy and gene editing. Treatment acceptability is essential for future clinical trials, so it is important for scientists and clinicians to be clear about the risks and benefits of these technologies, and how these are communicated to the public, while encouraging education about genetic therapies to a broad range of individuals.

Humanitarian Exchange Magazine
Number 75, May 2019
https://odihpn.org/magazine/making-humanitarian-action-work-for-women-and-girls/

Special Feature: Making humanitarian action work for women and girls
by HPN May 2019
The theme of this edition of Humanitarian Exchange, co-edited with Women Deliver, is making humanitarian action work for women and girls. Despite gains, including commitments made at
the World Humanitarian Summit, there is still much to be done to address the gendered impacts of humanitarian crises and improve gender-sensitive humanitarian action.

In the lead article, Jacqueline Paul advocates for feminist humanitarian action based on evidence that improvements in women's socio-economic status can reduce excess mortality among women after shocks. Jean Kemitare, Juliet Were and Jennate Eoomkham look at the role of local women’s rights organisations in preventing and responding to violence against women and girls, and Marcy Hersh and Diana Abou Abbas highlight opportunities for more concrete action on sexual and reproductive health in emergencies.

Citing experience from Vanuatu, Jane Newnham explains how women will choose to use contraceptives even during a humanitarian response, when services and counselling are delivered in an appropriate and responsive way. Drawing on experience in Bangladesh, Tamara Fetters and colleagues challenge the belief that abortion is a non-essential service, or too complicated for humanitarian actors to provide. Darcy Ataman, Shannon Johnson, Justin Cikuru and Jaime Cundy reflect on an innovative programme using music therapy to help survivors of trauma.

Emilie Rees Smith, Emma Symonds and Lauryn Oates highlight lessons from the STAGE education programme in Afghanistan, and Degan Ali and Deqa Saleh outline how African Development Solutions is helping women and girls take on leadership and decision-making roles in Somalia. Fiona Samuels and Taveeshi Gupta explore patterns of suicide among young people in Vietnam, with a particular focus on girls, and Subhashni Raj, Brigitte Laboukly and Shantony Moli illustrate the importance of a gendered approach to community-based disaster risk reduction in the South-West Pacific. Nicola Jones, Workneh Yadete and Kate Pincock draw on research in Ethiopia to explore the gender- and age-specific vulnerabilities of adolescents. The edition ends with an article by Julie Rialet-Cislaghi on how humanitarian responses can better address child marriage.

[Reviewed earlier]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 15, Issue 12, 2019
http://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/content
[Accessed 25 Jan 2020]
[No new digest content identified]

**Infectious Diseases of Poverty**
http://www.idpjournal.com/content
[Accessed 25 Jan 2020]
[Crowdsourcing in health and medical research: a systematic review]
Authors: Cheng Wang, Larry Han, Gabriella Stein, Suzanne Day, Cedric Bien-Gund, Allison Mathews, Jason J. Ong, Pei-Zhen Zhao, Shu-Fang Wei, Jennifer Walker, Roger Chou, Amy Lee, Angela Chen, Barry Bayus and Joseph D. Tucker
Content type: Scoping Review
20 January 2020

**International Health**
Volume 12, Issue 1, January 2020
https://academic.oup.com/inthealth/issue/12/1

*Original Articles*

**Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial**
Mohammad Ali, Dipika Sur, Suman Kanungo, Firdausi Qadri, Deok Ryun Kim ...
Int Health, Volume 12, Issue 1, January 2020, Pages 36–42,
https://doi.org/10.1093/inthealth/ihz069

**International Journal of Community Medicine and Public Health**
Vol 7, No 1 (2020) January 2020
https://www.ijcmph.com/index.php/ijcmph/issue/view/58
[Reviewed earlier]

**International Journal of Epidemiology**
Volume 48, Issue 6, December 2019
https://academic.oup.com/ije/issue/48/6
[Reviewed earlier]

**International Journal of Human Rights in Healthcare**
Volume 12 Issue 5
https://www.emerald.com/insight/publication/issn/2056-4902/vol/12/iss/5
[Reviewed earlier]

**International Journal of Infectious Diseases**
January 2020 Volume 90, p1-242
https://www.ijidonline.com/issue/S1201-9712(19)X0019-3
[Reviewed earlier]

**JAMA**
January 21, 2020, Vol 323, No. 3, Pages 203-288
http://jama.jamanetwork.com/issue.aspx
[New issue; No digest content identified]

**JAMA Pediatrics**
JBI Database of Systematic Review and Implementation Reports
January 2020 - Volume 18 - Issue 1
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
January 2020 Volume 66, Issue 1, p1-
https://www.jahonline.org/issue/S1054-139X(18)X0003-2
[New issue; No digest content identified]

Journal of Community Health
Volume 45, Issue 1, February 2020
https://link.springer.com/journal/10900/45/1
[Reviewed earlier]

Journal of Development Economics
Volume 142, January 2020
Special Issue on papers from "10th AFD-World Bank Development Conference held at CERDI, Clermont-Ferrand, on June 30 - July 1, 2017”
Edited by Caglar Ozden, David McKenzie, Hillel Rapoport
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 14 Issue 5, December 2019
http://journals.sagepub.com/toc/jre/current
Special Issue: Empirical Studies in Empirical Ethics
[Reviewed earlier]

Journal of Epidemiology & Community Health
January 2020 - Volume 74 - 1
https://jech.bmj.com/content/74/1
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 12, Issue 4 Pages: 233-336 November 2019
https://onlinelibrary.wiley.com/toc/17565391/current
Eradicating Measles: A Call for an Exceptional Coordinated Global Effort
David N Durrheim, Jon K Andrus, Günter Pfaff, Shahina Tabassum, Hyam Bashour ...
J Infect Dis, Volume 220, Issue 12, 15 December 2019, Pages 1870–1872,
https://doi.org/10.1093/infdis/jiz011

The Double-Edged Sword of Military Response to Societal Disruptions: A Systematic Review of the Evidence for Military Personnel as Pathogen Transmitters
Juliana N Zemke, Jose L Sanchez, Junxiong Pang, Gregory C Gray
J Infect Dis, Volume 220, Issue 12, 15 December 2019, Pages 1873–1884,
https://doi.org/10.1093/infdis/jiz400

Military personnel are at risk of serving as inadvertent vectors of infectious pathogens into or out of deployment zones. Such events published in peer-reviewed literature are summarized to provide historical context and suggestions for prevention and containment of future outbreaks.
Journal of Medical Ethics
January 2020 - Volume 46 - 1
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 6, Issue 4 (2019)
https://digitalrepository.aurorahealthcare.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
January 2020 Volume 216, p1-258
http://www.jpeds.com/current
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 25 Jan 2020]
[No new digest content identified]

Journal of Public Health Management & Practice
January/February 2020 - Volume 26 - Issue 1
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 40, Issue 4, December 2019
https://link.springer.com/journal/41271/40/4
[Reviewed earlier]

Journal of Refugee & Global Health
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
01 January 2020 Volume 17Issue 162
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]
Journal of Travel Medicine
Volume 26, Issue 8, 2019
https://academic.oup.com/jtm/issue/26/8
[Reviewed earlier]

Journal of Virology
February 2020; Volume 94, Issue 3
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Jan 25, 2020  Volume 395  Number 10220  p247-310, e14-e15
https://www.thelancet.com/journals/lancet/issue/current
[New issue; No digest content identified]

The Lancet Child & Adolescent Health
Volume 4, ISSUE 1, P1, January 01, 2020
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Volume 2, ISSUE 1, Pe1, January 01, 2020
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Volume 8, ISSUE 1, Pe1, January 01, 2020
http://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Volume 20, ISSUE 1, P1, January 01, 2020
http://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Volume 8, ISSUE 1, P1, January 01, 2020
http://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]
Does Animation Improve Comprehension of Risk Information in Patients with Low Health Literacy? A Randomized Trial
Enhanced visual effects, like animation, have the potential to improve comprehension of probabilistic risk information, particularly for those with lower health literacy
Ashley J. Housten, Geetanjali R. Kamath, Therese B. Bevers, Scott B. Cantor, Nickell Dixon, Andre Hite, Michael A. Kallen, Viola B. Leal, Liang Li, Robert J. Volk
First Published December 3, 2019; pp. 17–28
Nature Medicine
Volume 26 Issue 1, January 2020
https://www.nature.com/nm/volumes/26/issues/1
[Reviewed earlier]

Nature Reviews Genetics
Volume 21 Issue 1, January 2020
https://www.nature.com/nrg/volumes/21/issues/1
[Reviewed earlier]

Nature Reviews Immunology
Volume 20 Issue 1, January 2020
https://www.nature.com/nri/volumes/20/issues/1
[Reviewed earlier]

New England Journal of Medicine
January 23, 2020 Vol. 382 No. 4
http://www.nejm.org/toc/nejm/medical-journal
Original Articles
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
S.N. Ladhani and Others

Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia
H.S. Marshall and Others

Editorial
Good News and Bad News — 4CMenB Vaccine for Group B Neisseria meningitidisL.
H. Harrison and D.S. Stephens

Clinical Decisions
Choosing a Mass Immunization Program against Meningococcal
BK. Wu, E.K. Mulholland, and K.M. Edwards

Pediatrics
January 01, 2020; Volume 145,Issue 1
https://pediatrics.aappublications.org/content/145/1
[Reviewed earlier]

Pharmaceutics
Volume 12, Issue 1 (January 2020)
https://www.mdpi.com/1999-4923/12/1
[New issue, No digest content identified]
PharmacoEconomics
Volume 38, Issue 1, January 2020
https://link.springer.com/journal/40273/38/1
[Reviewed earlier]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 25 Jan 2020)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 25 Jan 2020)
[No new digest content identified]

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 25 Jan 2020)
Implementation of a mass canine rabies vaccination campaign in both rural and urban regions in southern Malawi
Research Article | published 23 Jan 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0008004

PLoS One
http://www.plosone.org/
(Accessed 25 Jan 2020)
Towards a bottom-up understanding of antimicrobial use and resistance on the farm: A knowledge, attitudes, and practices survey across livestock systems in five African countries
Mark A. Caudell, Alejandro Dorado-Garcia, Suzanne Eckford, Chris Creese, Denis K. Byarugaba, Kofi Afakyte, Tamara Chansa-Kabali, Folorunso O. Fasina, Emmanuel Kabali, Stella Kimihi, Tabitha Kimani, Geoffrey Mainda, Peter E. Mangesho, Francis Chimpangu, Kululeko Dube, Bashiru Boi Kikimoto, Eric Koka, Tendai Mugara, Bachana Rubegwa, Samuel Swiswa
Research Article | published 24 Jan 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0220274

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 25 Jan 2020]
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**
http://www.pnas.org/content/early/
[Accessed 25 Jan 2020]
[No new digest content identified]

**Prehospital & Disaster Medicine**
Volume 34 - Issue 6 - December 2019
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

**Preventive Medicine**
Volume 130  January 2020
[Reviewed earlier]

**Proceedings of the Royal Society B**
15 January 2020  Volume 287Issue 1918
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

**Public Health**
Volume 178  Pages 1-182 (January 2020)
Review article  Full text access
**Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis**
L.R. Avni-Singer, A. Yakely, S.S. Sheth, E.D. Shapiro, ... C.R. Oliveira
Pages 137-150

Research article  Full text access
**Supporting informed decision-making about vaccination: an analysis of two official websites**
M. Vivion, C. Hennequin, P. Verger, E. Dubé
Pages 112-119

Research article  Open access
**Consent for newborn screening: screening professionals' and parents' views**
F. Ulph, N. Dharni, R. Bennett, T. Lavender
Pages 151-158
Public Health Ethics
Volume 12, Issue 3, November 2019
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 135 Issue 1, January 2020
https://journals.sagepub.com/toc/phrg/135/1
[Reviewed earlier]

Qualitative Health Research
Volume 30 Issue 2, January 2020
http://qhr.sagepub.com/content/current
[Reviewed earlier]

Research Ethics
Volume 15 Issue 3-4, July-October 2019
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 25 Jan 2020]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Latest articles
[No new digest content identified]

Risk Analysis
Volume 40, Issue 1 Pages: 1-214 January 2020
https://onlinelibrary.wiley.com/toc/15396924/current
*Special Issue: Engineering Systems and Risk Analytics*
[Reviewed earlier]

Risk Management and Healthcare Policy
Original Research
Pharmacovigilance Perception and Knowledge Among Pharmacists and Interns in Saudi Arabia
Alshayban D, Mahmoud MA, Islam MA, Alshammari S, Alsulaiman D
Published Date: 24 January 2020

Science
24 January 2020 Vol 367, Issue 6476
http://www.sciencemag.org/current.dtl
[New issue; No digest content identified]

Science Translational Medicine
22 January 2020 Vol 12, Issue 527
https://stm.sciencemag.org/
[New issue; No digest content identified]

Social Science & Medicine
Volume 245 January 2020
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 25 Jan 2020]
[No new digest content identified]

Travel Medicine and Infectious Diseases
Volume 32 November–December 2019
[Reviewed earlier]

Tropical Medicine & International Health
Volume 24, Issue 12 Pages: i-iv, 1341-1475 December 2019
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 38, Issue 4 Pages 709-950 (22 January 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/4
[Reviewed earlier]
**Vaccines — Open Access Journal**
http://www.mdpi.com/journal/vaccines
(Accessed 25 Jan 2020)

**Open Access Article**

**Vaccination Programs for Adults in Europe, 2019**
by Dimitrios C. Cassimos, Evgnosia Effraimidou, Snezana Medic, Theoharis Konstantinidis, Maria Theodoridou and Helena C. Maltezou
Vaccines 2020, 8(1), 34; https://doi.org/10.3390/vaccines8010034 - 20 Jan 2020
Viewed by 97

**Abstract**

Background: While all European countries implement vaccination programs for children, there are gaps in terms of vaccination programs for adults. Methods: We studied the 2019 vaccination policies for adults in 42 European countries. Results: Vaccination programs for adults were in place in all countries. However, there were considerable differences between countries in terms of number of vaccinations, target populations and frame of implementation (recommended or mandatory vaccinations). In particular, the following vaccination policies were in place: influenza (42 countries), tetanus (31), diphtheria (30), pneumococcus (29), hepatitis B (20), pertussis (18), measles (14), human papilloma virus (14), meningococcus tetravalent A,C,W,Y (14), rubella (13), hepatitis A (11), mumps (11), poliomyelitis (10), herpes zoster (9), varicella (8), tick-born encephalitis (8), meningococcus B (6), rabies (6), Haemophilus influenzae type b (5), tuberculosis (3), typhoid fever (3), meningococcus C (2), and yellow fever (1). Seventeen countries implement mandatory vaccinations, mainly against diphtheria, tetanus and hepatitis B. Conclusions: There are significant differences in vaccination programs for adults in Europe. Routine vaccination programs for adults need to be strengthened. A consensus-based vaccination program is needed.

(This article belongs to the Special Issue Vaccination and Vaccine Effectiveness)

**Value in Health**
January 2020 Volume 23, Issue 1, p1-138
https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0002-7
[Reviewed earlier]

**Viruses**
Volume 12, Issue 1 (January 2020)
https://www.mdpi.com/1999-4915/12/1
[No new digest content identified]

* * * * *

**From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary**
Journal of Adolescent Health
Available online 20 January 2020
Original article
Calling the Shots? Adolescents' Influence on Human Papillomavirus Vaccine Decision-Making During Clinical Encounters
ATHR Fenton, TJ Eun, JA Clark, RB Perkins
The aim of the study was to examine adolescents' influence on human papillomavirus (HPV) vaccine decision-making and receipt during clinical visits.

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 25 Jan 2020
The Wuhan Coronavirus: Is China's Quarantine Ethical? - The Atlantic
China’s attempt to curb a viral outbreak is a radical experiment in authoritarian medicine
James Hamblin
January 24, 2020

BBC
http://www.bbc.co.uk/
Accessed 25 Jan 2020
[No new, unique, relevant content]

The Economist
http://www.economist.com/
Accessed 25 Jan 2020
[No new, unique, relevant content]

Financial Times
Coronavirus

China reports rising death toll from coronavirus
January 25, 2020

Forbes
http://www.forbes.com/
[No new, unique, relevant content]

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 25 Jan 2020
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 25 Jan 2020

The Wuhan Virus: How to Stay Safe
As China’s epidemic continues to spread, things may seem scary. Here are ten simple precautions that can protect you from contracting the coronavirus.
Report | January 25, 2020,
Laurie Garrett

The Guardian
http://www.guardiannews.com/
Accessed 25 Jan 2020
[No new, unique, relevant content]

New Yorker
http://www.newyorker.com/
Accessed 25 Jan 2020
[No new, unique, relevant content]

New York Times
http://www.nytimes.com/
Accessed 25 Jan 2020
Europe

With Wuhan Virus Genetic Code in Hand, Scientists Begin Work on a Vaccine
By Reuters Jan 25, 2020

Washington Post
https://www.washingtonpost.com/
Accessed 25 Jan 2020
[No new, unique, relevant content]
**Think Tanks et al**

Brookings  
http://www.brookings.edu/  
Accessed 25 Jan 2020  
[No new relevant content]

Center for Global Development  
http://www.cgdev.org/page/press-center  
Accessed 25 Jan 2020  
January 23, 2020  
**Why HTA and Pooled Purchasing Must Be at the Heart of Global Health Transitions**  
As middle income countries transition from donor support and increasingly use domestic funds to finance health programmes that have previously received substantial external aid, it is imperative that they build and use Health Technology Assessment capacities so that they can prioritise investment in good value technologies and services.  
Kalipso Chalkidou and Robert Hecht

CSIS  
https://www.csis.org/  
Accessed 25 Jan 2020  
[No new relevant content]

Council on Foreign Relations  
http://www.cfr.org/  
Accessed 25 Jan 2020  
[No new relevant content]

Kaiser Family Foundation  
https://www.kff.org/search/?post_type=press-release  
Accessed 25 Jan 2020  
[No new relevant content]

* * * *

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies,
INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *